# Ga-68-PSMA-11 in Men With Prostate Cancer

> **NCT05744115** · PHASE3 · TERMINATED · sponsor: **Timothy Hoffman** · enrollment: 38 (actual)

## Conditions studied

- Prostate Cancer
- Prostate Adenocarcinoma

## Interventions

- **DRUG:** Ga-68-PSMA-11

## Key facts

- **NCT ID:** NCT05744115
- **Lead sponsor:** Timothy Hoffman
- **Sponsor class:** FED
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-27
- **Primary completion:** 2022-04-14
- **Final completion:** 2022-04-14
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** The investigational product was approved by the FDA (12/20/2021) and is now commercially available
- **Last updated:** 2023-02-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05744115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05744115, "Ga-68-PSMA-11 in Men With Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05744115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*